Q-omics provides the consensus-scored KLF2P3 profile across patient tissues and cancer cell-line models. KLF2P3 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, KLF2P3 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, KLF2P3 RNA expression shows 12,252 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight LUAD, KIRC, and PCPG as cancer lineages where KLF2P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLF2P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLF2P3 survival associations across molecular data types. KLF2P3 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLF2P3 RNA expression–survival associations across cancer types. High KLF2P3 expression shows unfavorable associations in LUAD, LIHC, PRAD, THCA, UCS and OV. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for KLF2P3 RNA expression.
This table summarizes KLF2P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KLF2P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLF2P3 shows lower tumor expression in KIRC and THCA and higher tumor expression in KICH, BRCA and PRAD. The KIRC box plot shows higher KLF2P3 RNA expression in normal versus tumor tissue (log2 FC = −0.048, t-test p < 0.001).
This table shows molecular features associated with KLF2P3 in patient tissues and cancer cell lines. In patient samples, KLF2P3 shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set.
